Eli Lilly and Company (LLY) Fair Value & Analysis
Healthcare · CA · Market cap C$1.4T
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 20 days ago
Fair value updated Jun 24, 2026 — revised from C$16.72 to C$11.52 (−31.1%) since Jun 23, 2026. Share price +10.0% over the past month.
Price vs Fair Value (12 months)
12‑month range C$22.75 – C$41.71 · fair‑value band C$6.98 – C$31.18 · the C$39.86 price screens above the C$11.52 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Eli Lilly and Company (LLY) currently trades at C$39.86, while our model-based Fair Value estimate is C$11.52 — implying the stock looks roughly 71.1% overvalued today. We read business quality at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Eli Lilly and Company generated revenue of C$59.4B at a net margin of 31.0%. Revenue grew 53.9% year over year. It earns a return on equity of 96.5%. Net debt stands at C$35.2B. Fundamentals as of Jun 24, 2026
Our scenario range runs from C$6.98 (bear case) to C$31.18 (bull case); at C$39.86, the current price sits above that range. The share trades about 6% below its 52-week high and 76% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside — at -71%, LLY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic …
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Eli Lilly and Company reported revenue of C$65.2B in FY2025 versus C$28.5B in FY2022, a compound +31.7%/yr. Reported net income was C$20.6B in FY2025, compounding +49.0%/yr from FY2022.
Is LLY fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Johnson & Johnson, JNJ | C$29.84 | C$22.45 | -25% |
| AbbVie Inc 4AB | €196.25 | €89.57 | -54% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC ZEG | €160.70 | €128.63 | -20% |
| Novo Nordisk A/S NOV | €43.13 | €39.51 | -8% |
| Amgen Inc AMGN | $345.60 | $219.60 | -36% |
| Gilead Sciences, Inc GILD34 | R$320.43 | R$51.59 | -84% |
| Pfizer Inc PFE | $26.04 | $13.31 | -49% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Eli Lilly and Company (LLY) undervalued?
What is the fair value of LLY?
What is the quality score of LLY?
What is the revenue of Eli Lilly and Company (LLY)?
What is the net profit margin of LLY?
Does Eli Lilly and Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Eli Lilly and Company analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.